Profiles

Keywords
Last Name
Institution
 Back to Details

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Jamile Shammo and Parameswaran Venugopal.

 
Connection Strength
  
 
 
0.772
  
  1. Shammo JM, Usha L, Richardson KJ, Elliott E, Dewdney S, Venugopal P, Cobleigh M, Kuzel TM. Olaparib-Induced Severe Folate Deficiency in a Patient With Advanced Ovarian Cancer. J Oncol Pract. 2019 07; 15(7):405-407.
    View in: PubMed
    Score: 0.186
  2. Karmali R, Larson ML, Shammo JM, Gregory SA, O'Brien T, Venugopal P. Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma. Mol Clin Oncol. 2017 Apr; 6(4):627-633.
    View in: PubMed
    Score: 0.158
  3. Karmali R, Larson ML, Shammo JM, Basu S, Christopherson K, Borgia JA, Venugopal P. Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia. Leuk Lymphoma. 2015; 56(11):3135-42.
    View in: PubMed
    Score: 0.140
  4. Karmali R, Larson ML, Wooldridge JE, Gregory SA, O'Brien T, Shammo JM, Bueschel K, Venugopal P. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Leuk Lymphoma. 2011 Nov; 52(11):2097-104.
    View in: PubMed
    Score: 0.107
  5. Khandelwal A, Shah NB, Eichenseer P, Welker M, Miller I, Nangia J, Farhat M, Gimelfarb A, Kassar M, Batus M, Gezer S, Shammo J, Gregory S, Fung H, Venugopal P. Idiopathic hemophagocytic syndrome with a fulminant clinical course. Clin Adv Hematol Oncol. 2008 Aug; 6(8):587-90.
    View in: PubMed
    Score: 0.087
  6. Nathan S, Bharadwaj S, Luke K, Kalas L, Katz DA, Junaid Hussain M, Miller I, Hsu WT, Shammo J, Venugopal P, Ustun C. Significance of isolated deletion (20q) in donor cells after allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2020 08; 61(8):2008-2011.
    View in: PubMed
    Score: 0.049
  7. Karmali R, Kassar M, Venugopal P, Shammo JM, Fung HC, Bayer R, O'Brien T, Gregory SA. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):467-74.
    View in: PubMed
    Score: 0.027
  8. Rao R, Shammo JM, Enschede SH, Porter C, Adler SS, Venugopal P, Gregory SA. The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma. Clin Lymphoma. 2005 Jun; 6(1):26-30.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.